|
Synonyms: AD-65585 | ALN-65585 | ALN-G01 | Oxlumo®
lumasiran is an approved drug (EMA, FDA & UK MHRA (2020))
Compound class:
Nucleic acid
Comment: Lumasiran is a double-stranded small interfering ribonucleic acid (siRNA) drug. It targets HAO1 mRNA as a mechanism to reduce the hepatic oxalate overproduction that is responsible for disease pathology in patients with primary hyperoxaluria type 1 (PH1) [1]. We have been unable to locate a full chemical SMILES for the drug, or its HELM notation.
|
Nucleic Acid Sequence  |
|
|
(3'-5')G=A=C-U-U-U-C-A-U-C-C-U-G-G-A-A-A-U-A-U-A-R1 (5'-3')A=C=C-U-G-A-A-A-G-U-A-G-G-A-C-C-U-U-U-A-U=A=U |
|
